RxDoctor Payments Data

George Osuchukwu, MD

Nephrology · Victoria, TXNPI 1962612887

Payments from drug & device makers

$27,442in general payments, 2019–2025

Across 73 payments — averaging $375.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$13K
  • Chiesi USA, Inc.$7K
  • Akebia Therapeutics Inc$7K
  • Amgen$186
  • La Jolla Pharmaceutical Company$106
  • Boehringer Ingelheim$106
  • plus $687 from 14 others

What the payments were for

  • Consulting fees$9,92036%
  • Speaking & faculty fees$13,51349%
  • Travel & lodging$1,9417%
  • Food & beverage$2,0688%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,442 in reported general payments places this provider in the 85th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$425,895
Medicare patients
750
Services billed
3,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin97$91,423
FarxigaDapagliflozin Propanediol44$49,237
VelphoroSucroferric Oxyhydroxide17$47,663
XphozahTenapanor Hcl11$38,681
Sevelamer Carbonate49$13,320
Calcium Acetate90$8,432
Calcitriol117$3,062
Nifedipine ErNifedipine28$2,196
Midodrine Hcl15$1,874
Megestrol Acetate13$1,208
Losartan Potassium134$1,172
Furosemide172$1,081
Hydralazine Hcl72$884
Gentamicin Sulfate19$730
Amlodipine Besylate133$729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$106$91,42397 claims
AstraZenecaFarxiga$103$49,23744 claims
Fresenius USA Marketing, Inc.Velphoro$24$47,66317 claims
ANI Pharmaceuticals, Inc.Valsartan$80$22312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Victoria

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →